

**VIRGINIA MEDICAID  
REQUEST FOR  
Service AUTHORIZATION  
KETEK®**



**COMMONWEALTH of VIRGINIA  
Department of Medical Assistance Services**

Requests for service authorization (SA) must include patient name, Medicaid ID#, drug name, and appropriate clinical information to support the request on the basis of medical necessity. Please include all requested information; incomplete forms will delay the SA process. **Submission of documentation does not guarantee coverage by the Department of Medical Assistance Services and final coverage decisions may be affected by the specific Medicaid Limitations.**

The completed form may be **FAXED TO 800-932-6651**. Requests may be phoned to 800-932-6648.

**Requests may be mailed to:** Magellan Medicaid Administration / 11013 W. Broad St / Glen Allen, VA 23060 / ATTN: MAP  
All questions must be answered. By signing this request, the physician accepts understanding of the contraindications and warnings concerning the use of Ketek® and acknowledges that the benefits of using the drug outweigh the possible risks.

Today's Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

Requested Start Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

**PATIENT INFORMATION**

**Name: (Last, First)** \_\_\_\_\_ **Medicaid ID#:** \_\_\_\_\_

**Date of Birth:** \_\_\_\_/\_\_\_\_/\_\_\_\_ **Gender:** ☐ Male ☐ Female

**DRUG INFORMATION**

**Drug Name, Dosage Form & Strength:** \_\_\_\_\_ **Quantity Per Day:** \_\_\_\_\_

Is KETEK® is being used for the treatment of community-acquired pneumonia (of mild to moderate severity) Yes No

Is the microorganism being treated one of the following? Yes No If yes which one? \_\_\_\_\_

*Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydomphila pneumoniae, or Mycoplasma pneumoniae.*

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Yes No If yes, please explain: \_\_\_\_\_

**Contraindications**

- KETEK® is contraindicated in patients with myasthenia gravis. Exacerbations of myasthenia gravis have been reported in patients and sometimes occurred within a few hours of the first dose of KETEK. Reports have included fatal and life threatening acute respiratory failure with a rapid onset and progression.
- KETEK® is contraindicated in patients with previous history of hepatitis and/or jaundice associated with the use of KETEK® tablets, or any macrolide antibiotic.
- KETEK® is contraindicated in patients with a history of hypersensitivity to telithromycin and/or any components of KETEK® tablets, or any macrolide antibiotic.
- Concomitant administration of KETEK® with cisapride or pimozide is contraindicated.

**Warnings**

**Possible:** Hepatotoxicity; prolongation of the QTc interval that may lead to an increased risk for ventricular arrhythmias, including torsades de pointes; Visual disturbances particularly in slowing the ability to accommodate and the ability to release accommodation. Visual disturbances included blurred vision, difficulty focusing, and diplopia. Loss of consciousness has been reported in post-marketing adverse event reports of transient loss of consciousness including some cases associated with vagal syndrome.

**PRESCRIBER INFORMATION**

**Name (print):** \_\_\_\_\_ **NPI Number:** \_\_\_\_\_

**Phone Number:** (\_\_\_\_) \_\_\_\_\_-\_\_\_\_ **Fax Number:** (\_\_\_\_) \_\_\_\_\_-\_\_\_\_

**Signature of Prescribing Provider:** \_\_\_\_\_

*By signing this request, I understand the contraindications and warnings concerning the use of Ketek® and acknowledge that the benefits of using the drug outweigh the possible risks.*

**PLEASE INCLUDE ALL REQUESTED INFORMATION  
INCOMPLETE FORMS WILL DELAY THE PRIOR AUTHORIZATION PROCESS**

FAX TO 800-932-6651  
SERVICE AUTHORIZATION CRITERIA IS SUBJECT TO CHANGE  
<http://www.virginiamedicaidpharmacyservices.com>